<DOC>
	<DOCNO>NCT02852395</DOCNO>
	<brief_summary>This 3-part study evaluate safety , tolerability , pharmacokinetics , pharmacodynamics JNJ-48816274 healthy participant administration single repeat dos , evaluate potential effectiveness treat insomnia .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics JNJ-48816274</brief_title>
	<detailed_description />
	<criteria>Must healthy assess medical history safety evaluation perform screening Has body mass index 18 30 kilogram per square meter ( kg/m2 ) body weight less 50 kg Must willing able abide prohibition restriction study , include requirement contraception Women must childbearing potential either postmenapausal permanently sterilize Part 2 Only : Maintains regular sleepwake cycle measure sleep diary watch measure activity Has habitual ( majority day ) bedtime duration sleep meet study requirement Current history clinically significant medical psychiatric illness , recent major surgery blood loss/donation Any current sleepwake disorder , recent night shift work , history insomnia within last 5 year Man pregnant female partner Woman breastfeeding Is participate participate within last 3 month study investigational drug medical device Tests positive history human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C , active liver disease Drug alcohol abuse within last 5 year , nicotine use within last 3 month , test positive alcohol , drug abuse , nicotine Routinely consumes excessive amount caffeine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>